Drug Approvals
Johnson & Johnson or Pfizer: Which Big Pharma Dividend Stock Is a Better Buy?
Healthcare giants Johnson & Johnson and Pfizer offer a tough choice for dividend investors seeking the best returns.
What's Next for Biogen After It Terminates Trials for Alzheimer's Drug?
Biogen has to now be considered a more likely buyout target given the breadth of its product portfolio.
Activists Aim to Eliminate Dual Role for Allergan CEO Saunders
David Tepper's Appaloosa LP renews calls for changes at the top.
I Like the Long Side of Bristol-Myers Squibb
Let's see what the charts and indicators look like.
Chart of the Day, Part 1: Canopy Growth Could Be Key to Constellation Long Term
Analysts have noted that the weed leader's momentum is set to burn higher moving forward.
Real Money Goes Behind the Scenes of the Budding Cannabis Industry
In the interest of due diligence, we went and took a close look at the ground floor of the newest investment craze.
Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Pfizer Stock Slides Slightly as Drug-Maker Prepares Price Increases
Pfizer may have poked the bear.
Eli Lilly's Elanco Offload Offers Acquisition Flexibility
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken
Once the safest stocks in the book, the big-cap drug companies are now toxic.